Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 553

Sort by

Sort Order Select

Journal Articles

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Müller-Tidow, Stephen Gottschalk, Cliona M. Rooney

Blood (2021) 138 (4): 318–330.

https://doi.org/10.1182/blood.2020008221

Published: 2021

Includes: Supplemental data

Journal Articles

CD27 is required for protective lytic EBV antigen–specific CD8 + T-cell expansion

Yun Deng, Bithi Chatterjee, Kyra Zens, Hana Zdimerova, Anne Müller, Patrick Schuhmachers, Laure-Anne Ligeon, Antonino Bongiovanni, Riccarda Capaul, Andrea Zbinden, Angelika Holler, Hans Stauss, Wolfgang Hammerschmidt, Christian Münz

Blood (2021) 137 (23): 3225–3236.

https://doi.org/10.1182/blood.2020009482

Published: 2021

Includes: Supplemental data

Journal Articles

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Jonathan C Poe, PhD, Dadong Zhang, PhD, Jichun Xie, PhD, Rachel A. DiCioccio, BS, Xiaodi Qin, MS, Jiyuan Fang, MS, Vincent T. Ho, MD, Jeremy J. Rose, MS, Steven Z. Pavletic, MD MS, Frances T. Hakim, PhD, Wei Jia, MD PhD, Amy N. Suthers, PhD, Mitchell E. Horwitz, MD, David A. Rizzieri, MD, William C. McManigle, MD, Nelson J. Chao, MD, Kouros Owzar, PhD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 874.

https://doi.org/10.1182/blood-2019-130928

Published: 2019

Journal Articles

Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma

Marie C Bene, PharmD,DPhil, Nelly Robillard, PhD, Philippe Moreau, MD, Soraya Wuilleme, PharmD, PhD

Blood (2019) 134 (Supplement_1): 1799.

https://doi.org/10.1182/blood-2019-130607

Published: 2019

Journal Articles

MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry

Kiyoshi Okazuka, MD, Tadao Ishida, MD PhD, Jun Sakamoto, Nobuhiro Tsukada, MD PhD, Kenshi Suzuki, MD PhD

Blood (2019) 134 (Supplement_1): 1832.

https://doi.org/10.1182/blood-2019-123900

Published: 2019

Journal Articles

Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

Deeksha Vishwamitra, Christine Mantis, PhD, Dipica Haribhai, PhD, Tamar Uziel, PhD, Joel D. Leverson, PhD, James M. Pauff, MD PhD, Orlando F. Bueno, MD PhD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD

Blood (2019) 134 (Supplement_1): 1896.

https://doi.org/10.1182/blood-2019-128672

Published: 2019

Journal Articles

A Novel 10-Fluorochrome Multiparameter Flow Cytometry (MFC) Panel for Precise Plasma Cell (PC) and MRD Assessment in Clinical Routine of Multiple Myeloma (MM) Patients and throughout the Disease Course

Veronika Riebl, Sandra M. Woerner, Dagmar Wider, Marie Follo, Stefan J. Mueller, Cornelius Miething, Mihaela Zlei, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 1789.

https://doi.org/10.1182/blood-2019-124680

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

Tim Sauer, MD, Kathan Parikh, Sandhya Sharma, Bilal Omer, MD, Stephen Gottschalk, MD, Cliona M. Rooney, PhD

Blood (2019) 134 (Supplement_1): 1932.

https://doi.org/10.1182/blood-2019-125534

Published: 2019

Journal Articles

Influence of CD27 - CD28 - T-Cells on the Therapeutic Outcome in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma after CART-Infusion

Nina Worel, MD, Katharina Pfistershammer, Winfried Pickl, Marion Heinz, RN, MPhil, Martina Schlager, Beate Pribitzer, Andreas Tanzmann, MD, Ulrich Jaeger, MD, Georg Hopfinger

Blood (2019) 134 (Supplement_1): 1935.

https://doi.org/10.1182/blood-2019-126191

Published: 2019

Journal Articles

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Hidekazu Itamura, MD PhD, Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Kazutaka Kitaura, DVM, PhD, Seiji Okada, MD PhD, Tadasu Shin-I, PhD, Ryuji Suzuki, DVM, PhD, Akifumi Takaori-Kondo, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 1929.

https://doi.org/10.1182/blood-2019-128913

Published: 2019

Journal Articles

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Camille Bigenwald, MD, Amir Horowitz, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Richa Rai, PhD, Stella Melana, PhD, Erin P. Demakos, RN, Miriam Merad, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 2986.

https://doi.org/10.1182/blood-2019-124887

Published: 2019

Journal Articles

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3083.

https://doi.org/10.1182/blood-2019-122398

Published: 2019

Journal Articles

CLL Increases the Frequency of CD4 + HLADR + PD1 + T Cells That Demonstrate an Exhaustion Gene Signature and Potential Prognostic Value for Disease Progression

Peter M Henley, BMedSc, Christopher Fegan, MB, MD FRCP, FRCPath, Stephen Man, PhD

Blood (2019) 134 (Supplement_1): 3033.

https://doi.org/10.1182/blood-2019-128546

Published: 2019

Journal Articles

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

Maissa Mhibik, PhD, Erika M Gaglione, Amy Blackburn, Keyvan Keyvanfar, Clare Sun, MD, Inhye E Ahn, MD, Maria Joao Baptista, Junpeng Qi, PhD, Christoph Rader, PhD, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 2861.

https://doi.org/10.1182/blood-2019-126186

Published: 2019

Journal Articles

Novel Immune Checkpoint Deficiency and Susceptibility to EBV-Associated Lymphoma

Ido Somekh, Thomas Magg, PhD, Alejandro Gallón Duque, Tali Stauber, MD, Atar Lev, MSc, Ekrem Unal, MD, Amos J. Simon, PhD, Meino Rohlfs, PhD, Raffaele Conca, MSc, Megumi Tatematsu, PhD, Fabian Hauck, MD PhD, Raz Somech, MD PhD, Christoph Klein, MD PhD

Blood (2019) 134 (Supplement_1): 2326.

https://doi.org/10.1182/blood-2019-128296

Published: 2019

Journal Articles

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

James Aries, Sarah Charrot, Jennifer Ball, Matthew Mee, Symeon Theocharidis, Sofie Van Gassen, Sameena Iqbal, John G. Gribben, MD DSc, Jeff Davies, MBBS, PhD

Blood (2019) 134 (Supplement_1): 595.

https://doi.org/10.1182/blood-2019-124875

Published: 2019

Journal Articles

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Blood (2019) 134 (Supplement_1): 506.

https://doi.org/10.1182/blood-2019-123974

Published: 2019

Journal Articles

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

Stephan M Tirier, PhD, Jan-Philipp Mallm, PhD, Nicola Casiraghi, PhD, Hana Susak, PhD, Nicola Giesen, MD, Alexandra M Poos, PhD, Katharina Bauer, Anja Baumann, Lukas John, MD, Jing Xu, PhD, Lara Klett, MSc, Carsten Müller-Tidow, MD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Niels Weinhold, PhD, Oliver Stegle, PhD, Karsten Rippe, PhD, Marc S. Raab, MD

Blood (2019) 134 (Supplement_1): 571.

https://doi.org/10.1182/blood-2019-128625

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

NARROW

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

CD27 is required for protective lytic EBV antigen–specific CD8 + T-cell expansion

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma

MRD Detection in Myeloma Cells: Comparison between Inexpensive 1-Tube 10 Color Multiparameter Flow Cytometry and Euroflow Multiparameter Flow Cytometry

Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

A Novel 10-Fluorochrome Multiparameter Flow Cytometry (MFC) Panel for Precise Plasma Cell (PC) and MRD Assessment in Clinical Routine of Multiple Myeloma (MM) Patients and throughout the Disease Course

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

Influence of CD27 - CD28 - T-Cells on the Therapeutic Outcome in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma after CART-Infusion

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

CLL Increases the Frequency of CD4 + HLADR + PD1 + T Cells That Demonstrate an Exhaustion Gene Signature and Potential Prognostic Value for Disease Progression

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

Novel Immune Checkpoint Deficiency and Susceptibility to EBV-Associated Lymphoma

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only